Cargando…
INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
Early pharmacological interventions on transgenic models of hypertrophic cardiomyopathy (HCM) using angiotensin receptor blockers (ARBs) may be effective in preventing development of clinical phenotype or causing phenotype regression in early stages of disease. In the clinical setting, however, the...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bloomsbury Qatar Foundation Journals
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374100/ https://www.ncbi.nlm.nih.gov/pubmed/25830151 http://dx.doi.org/10.5339/gcsp.2015.7 |
_version_ | 1782363430948175872 |
---|---|
author | Olivotto, Iacopo Ashley, Euan A. |
author_facet | Olivotto, Iacopo Ashley, Euan A. |
author_sort | Olivotto, Iacopo |
collection | PubMed |
description | Early pharmacological interventions on transgenic models of hypertrophic cardiomyopathy (HCM) using angiotensin receptor blockers (ARBs) may be effective in preventing development of clinical phenotype or causing phenotype regression in early stages of disease. In the clinical setting, however, the effects of ARBs on HCM phenotype have been less consistent. INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) was designed to assess the effect of 100 mg of losartan in promoting the regression of LV hypertrophy in HCM. The primary end-point of the study was the reduction in LV mass assessed by MRI or computed tomography. After 12 months, no reduction in LV mass was observed in the losartan arm, and there was no difference in LV mass change with the placebo arm. The same was true for all secondary endpoints. The implications of these findings are discussed in the light of further, ongoing study targeting the HCM phenotype. |
format | Online Article Text |
id | pubmed-4374100 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Bloomsbury Qatar Foundation Journals |
record_format | MEDLINE/PubMed |
spelling | pubmed-43741002015-03-31 INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) Olivotto, Iacopo Ashley, Euan A. Glob Cardiol Sci Pract Lessons from the Trials Early pharmacological interventions on transgenic models of hypertrophic cardiomyopathy (HCM) using angiotensin receptor blockers (ARBs) may be effective in preventing development of clinical phenotype or causing phenotype regression in early stages of disease. In the clinical setting, however, the effects of ARBs on HCM phenotype have been less consistent. INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) was designed to assess the effect of 100 mg of losartan in promoting the regression of LV hypertrophy in HCM. The primary end-point of the study was the reduction in LV mass assessed by MRI or computed tomography. After 12 months, no reduction in LV mass was observed in the losartan arm, and there was no difference in LV mass change with the placebo arm. The same was true for all secondary endpoints. The implications of these findings are discussed in the light of further, ongoing study targeting the HCM phenotype. Bloomsbury Qatar Foundation Journals 2015-01-26 /pmc/articles/PMC4374100/ /pubmed/25830151 http://dx.doi.org/10.5339/gcsp.2015.7 Text en © 2015 Olivotto, Ashley, licensee Bloomsbury Qatar Foundation Journals. This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Lessons from the Trials Olivotto, Iacopo Ashley, Euan A. INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) |
title | INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) |
title_full | INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) |
title_fullStr | INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) |
title_full_unstemmed | INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) |
title_short | INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan) |
title_sort | inherit (inhibition of the renin angiotensin system in hypertrophic cardiomyopathy and the effect on hypertrophy—a randomised intervention trial with losartan) |
topic | Lessons from the Trials |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374100/ https://www.ncbi.nlm.nih.gov/pubmed/25830151 http://dx.doi.org/10.5339/gcsp.2015.7 |
work_keys_str_mv | AT olivottoiacopo inheritinhibitionofthereninangiotensinsysteminhypertrophiccardiomyopathyandtheeffectonhypertrophyarandomisedinterventiontrialwithlosartan AT ashleyeuana inheritinhibitionofthereninangiotensinsysteminhypertrophiccardiomyopathyandtheeffectonhypertrophyarandomisedinterventiontrialwithlosartan |